{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:53:33Z","timestamp":1788411213267,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.esmoop.2022.100745","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:45:29Z","timestamp":1671540329000},"page":"100745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Targeting KRASG12C in colorectal cancer: the beginning of a new era"],"prefix":"10.1016","volume":"8","author":[{"given":"D.","family":"Ciardiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.esmoop.2022.100745_bib1","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100745_bib2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A\u00a0genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100745_bib3","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.3390\/ijms23084120","article-title":"KRAS: a druggable target in colon cancer patients","volume":"23","author":"Negri","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100745_bib4","first-page":"372","article-title":"Clinical management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2022.100745_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102023","article-title":"Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: what does still need to be addressed?","volume":"86","author":"Martini","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"7477","key":"10.1016\/j.esmoop.2022.100745_bib6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100745_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100745_bib8","doi-asserted-by":"crossref","first-page":"S1294","DOI":"10.1016\/j.annonc.2021.08.2093","article-title":"LBA6 KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation","volume":"32","author":"Weiss","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100745_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13046-021-02225-w","article-title":"The path to the clinic: a comprehensive review on direct KRASG12C inhibitors","volume":"41","author":"Kwan","year":"2022","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100745_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc2030638","article-title":"Distribution of KRASG12C somatic mutations across race, sex, and cancer type","volume":"384","author":"Nassar","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100745_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100567","article-title":"Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)","volume":"7","author":"Ciardiello","year":"2022","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100745_bib12","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/onco.13870","article-title":"The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: a multicenter retrospective observational study","volume":"26","author":"Chida","year":"2021","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100745_bib13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/oncolo\/oyac077","article-title":"Real-world study of characteristics and treatment outcomes among patients with KRAS p.G12C-mutated or other KRAS mutated metastatic colorectal cancer","volume":"27","author":"Fakih","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2022.100745_bib14","article-title":"Comprehensive clinical and molecular characterization of KRASG12C-mutant colorectal cancer","volume":"5","author":"Henry","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2022.100745_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","article-title":"Targeting KRAS mutant cancers: from druggable therapy to drug resistance","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100745_bib16","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and structural analysis of common cancer-associated KRAS mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100745_bib17","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"issue":"7781","key":"10.1016\/j.esmoop.2022.100745_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100745_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"issue":"13","key":"10.1016\/j.esmoop.2022.100745_bib20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100745_bib21","series-title":"KRYSTAL-1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation","author":"Klempner","year":"2022"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100745_bib22","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2022.100745_bib23","article-title":"Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: safety and efficacy for phase 1B full expansion cohort","author":"Kuboki","year":"2022","journal-title":"ESMO Congress"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100745_bib24","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/oncolo\/oyab080","article-title":"Phase I study of JNJ-74699157 in patients with advanced solid tumors harboring the KRAS G12C mutation","volume":"27","author":"Wang","year":"2022","journal-title":"Oncologist"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2022.100745_bib25","first-page":"S136","article-title":"Phase Ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation","volume":"33","author":"Desai","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100745_bib26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100745_bib27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrc3151","article-title":"Targeting protein prenylation for cancer therapy","volume":"11","author":"Berndt","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100745_bib28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mdf173","article-title":"A\u00a0phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan","volume":"13","author":"Sharma","year":"2002","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100745_bib29","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","article-title":"Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer","volume":"22","author":"Van Cutsem","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100745_bib30","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1038\/s41388-020-1364-7","article-title":"Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal","volume":"39","author":"Chai","year":"2020","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100745_bib31","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/jcmm.12618","article-title":"Functions of Shp2 in cancer","volume":"19","author":"Zhang","year":"2015","journal-title":"J\u00a0Cell Mol Med"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100745_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110993","article-title":"KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy","volume":"39","author":"Ryan","year":"2022","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100745_bib33","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1073\/pnas.1812963116","article-title":"Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction","volume":"116","author":"Hillig","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"394","key":"10.1016\/j.esmoop.2022.100745_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal5253","article-title":"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS","volume":"9","author":"Ross","year":"2017","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100745_bib35","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/bjc.2015.144","article-title":"Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer","volume":"112","author":"Macarulla","year":"2015","journal-title":"Br J Cancer"},{"issue":"19","key":"10.1016\/j.esmoop.2022.100745_bib36","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.19.02654","article-title":"Phase I, open-label, dose-escalation\/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors","volume":"38","author":"Desai","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2022.100745_bib37","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1038\/sj.onc.1201105","article-title":"K-ras modulates the cell cycle via both positive and negative regulatory pathways","volume":"14","author":"Fan","year":"1997","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.esmoop.2022.100745_bib38","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1158\/0008-5472.CAN-22-0198","article-title":"Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4\/6","volume":"82","author":"Sorokin","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100745_bib39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2019.04.003","article-title":"Immunotherapy of colorectal cancer: challenges for therapeutic efficacy","volume":"76","author":"Ciardiello","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"23","key":"10.1016\/j.esmoop.2022.100745_bib40","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100745_bib41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100745_bib42","series-title":"CodeBreaK 100\/101: first report of safety\/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC","author":"Li","year":"2022"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100745_bib43","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.ccell.2022.07.005","article-title":"A\u00a0covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"issue":"25","key":"10.1016\/j.esmoop.2022.100745_bib44","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.esmoop.2022.100745_bib45","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","article-title":"Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer","volume":"26","author":"Adachi","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922003799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922003799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:30:57Z","timestamp":1761856257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922003799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2059702922003799"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100745","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting KRASG12C in colorectal cancer: the beginning of a new era","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100745","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100745"}}